FI92195B - Förfarande för framställning av terapeutiskt användbara pyridinderivat - Google Patents
Förfarande för framställning av terapeutiskt användbara pyridinderivat Download PDFInfo
- Publication number
- FI92195B FI92195B FI890257A FI890257A FI92195B FI 92195 B FI92195 B FI 92195B FI 890257 A FI890257 A FI 890257A FI 890257 A FI890257 A FI 890257A FI 92195 B FI92195 B FI 92195B
- Authority
- FI
- Finland
- Prior art keywords
- mmol
- alkyl
- branched
- straight
- phenyl
- Prior art date
Links
- 0 C*C(CC(*)CCC(C1C(CC2)C=CC2F)=C(C(C)C)NC(C(C)C)=C1C=CC(*)CC(*)O)O Chemical compound C*C(CC(*)CCC(C1C(CC2)C=CC2F)=C(C(C)C)NC(C(C)C)=C1C=CC(*)CC(*)O)O 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Furan Compounds (AREA)
Claims (13)
1. Förfarande för framställning av terapeutiskt användbara pyridinderivat med formeln I 5 1 R1 H H 7. jC I 7 r'00C-HoC-C-HoC-HC-HC=HC—-^n^-CH=CH-CH-CH--C-CHo-C00R 2 I 2 I 7 | 2 I 2 in OH OH , JU Λ „ OH OH 1U R3^VN'^r2 (I) väri R1 Sr väte eller halogen, R2 är C3_6-cykloalkyl eller rakkedjad eller förgrenad C1.6-15 alkyl, R3 är C3_6-cykloalkyl eller rakkedjad eller förgrenad C^j-alkyl, som kan vara substituerad med fenyl, eller fenyl och R7 är väte, rakkedjad eller förgrenad Cj^-alkyl eller en 20 natrium- eller kalciumkatjon, kännetecknat därav, att man reducerar ett keton med den allmänna formeln VIII R1
25 Uj) 0 ? R800C-H2C-C-H2C-HC-HC=HC--rjX<^v—CH=CH-<pH-CH2-C-CH2-COOR8 OH 2 0H R3/^N (VIII) 30 väri R1, R2 och R3 betecknar samma som ovan och R8 är rakkedjad eller förgrenad C1_12-alkyl, vid framställning av syror förtvälar estrarna, vid framställning av salter förtvälar estrarna, och 35 eventuellt separerar isomererna. 66 92,>5
2. Förfarande enligt patentkrav 1, k ä n n e - t e c k n a t därav, att reduceringen utförs vid en tem-peratur av -80 - +30 °C.
3. Keton med formeln VIII
5 R1 Φ y r8ooc-h0c-c-h9c-hc-hc=hc ch=ch-ch-ch2-c-ch2-coor8
2. I I HO oJlJL o 0H
10 R3/^N-^r2 K (VIII) väri R1 är väte eller halogen, R2 är C3.6-cykloalkyl eller rakkedjad eller förgrenad Cj_6-15 alkyl, R3 är C3_6-cykloalkyl eller rakkedjad eller förgrenad C1_6-alkyl, som kan vara substituerad med fenyl, eller fenyl och R8 är rakkedjad eller förgrenad Cj.^-alkyl. 20 4. Förfarande för framställning av keton med for meln VIII R1
0 O
25 R800C-HoC-C-H^C-HC-HC=HC·—CH=CH-CH-CHo-C-CH--C00R8 2 2 | T ^ f | 2 2 H0 , OH (VIII) väri
30 R1 är väte eller halogen, R2 är C3_6-cykloalkyl eller rakkedjad eller förgrenad C1.6-alkyl, R3 är C3_6-cykloalkyl eller rakkedjad eller förgrenad C^-alkyl, som kan vara substituerad med fenyl, eller fenyl 35 och n 921 95 67 R8 är rakkedjad eller förgrenad C1.12-alkyl, kännetecknat därav, att man omsätter en alde-hyd med den allmänna formeln IX
5 R1 0 rii 0 ηΛ\ i (IX) 10 r3/^N^\r2 väri R1, R2 och R3 betecknar samma som ovan, i ett inert lösningsmedel i närvaro av en bas med en acet-15 ättikester med den allmänna formeln X 0 11 8 h3c-c-ch2-coor (X) 20 väri R8 betecknar samma som ovan.
5. Förfarande enligt patentkrav 4, kännetecknat därav, att reaktionen utförs vid en tempe-ratur av -80 - +50 °C. f #
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE3801440 | 1988-01-20 | ||
DE3801440A DE3801440A1 (de) | 1988-01-20 | 1988-01-20 | Disubstituierte pyridine |
IT8821587A IT8821587A0 (it) | 1988-07-29 | 1988-07-29 | Piridine disostituite. |
IT2158788 | 1988-07-29 |
Publications (4)
Publication Number | Publication Date |
---|---|
FI890257A0 FI890257A0 (sv) | 1989-01-18 |
FI890257A FI890257A (sv) | 1989-07-21 |
FI92195B true FI92195B (sv) | 1994-06-30 |
FI92195C FI92195C (sv) | 1994-10-10 |
Family
ID=25864088
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI890257A FI92195C (sv) | 1988-01-20 | 1989-01-18 | Förfarande för framställning av terapeutiskt användbara pyridinderivat |
Country Status (16)
Country | Link |
---|---|
US (1) | US4968689A (sv) |
EP (1) | EP0325129B1 (sv) |
JP (1) | JP2712107B2 (sv) |
KR (1) | KR890011847A (sv) |
CN (1) | CN1034716A (sv) |
AT (1) | ATE111081T1 (sv) |
AU (1) | AU614810B2 (sv) |
DE (1) | DE58908290D1 (sv) |
DK (1) | DK23289A (sv) |
ES (1) | ES2058343T3 (sv) |
FI (1) | FI92195C (sv) |
HU (1) | HU208691B (sv) |
IL (1) | IL88971A (sv) |
NO (1) | NO890046L (sv) |
NZ (1) | NZ227636A (sv) |
PT (1) | PT89478B (sv) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3505382A1 (de) * | 1985-02-16 | 1986-08-21 | Accord-Landmaschinen Heinrich Weiste & Co Gmbh, 4770 Soest | Zweischeibenduengerstreuer |
NO177005C (no) * | 1988-01-20 | 1995-07-05 | Bayer Ag | Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen |
US5506219A (en) * | 1988-08-29 | 1996-04-09 | E. R. Squibb & Sons, Inc. | Pyridine anchors for HMG-CoA reductase inhibitors |
FI94339C (sv) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Förfarande för framställning av farmaceutiskt användbar /R-(R*,R*)/-2-(4-fluorfenyl)- , -dihydroxi-5-(1-metyletyl)-3-fenyl-4-/(fenylamino)karbonyl/-1H-pyrrol-1-heptansyra och farmaceutiskt användbara salter därav |
DE3925636A1 (de) * | 1989-08-03 | 1991-02-07 | Bayer Ag | Imino-substituierte pyridine |
US5183897A (en) * | 1989-08-03 | 1993-02-02 | Bayer Aktiengesellschaft | Certain intermediate imino-substituted pyridines |
DE3929507A1 (de) * | 1989-09-06 | 1991-03-07 | Bayer Ag | Substituierte amino-pyridine |
PT657432E (pt) * | 1993-12-10 | 2003-07-31 | Bayer Ag | 1,4-di-hidropiridinas fenil-substituidas com actividade cerebral |
AR008789A1 (es) * | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
US6812345B2 (en) | 2000-06-15 | 2004-11-02 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
US6627636B2 (en) | 2000-06-15 | 2003-09-30 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
US6620821B2 (en) | 2000-06-15 | 2003-09-16 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
DE10135013A1 (de) * | 2001-07-18 | 2003-01-30 | Bayer Ag | Herstellung von Pyridylverbindungen |
US7659281B2 (en) | 2006-04-25 | 2010-02-09 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0098690B1 (en) * | 1982-06-14 | 1987-09-09 | Takeda Chemical Industries, Ltd. | Vinyl carboxylic acid derivatives, their production and use |
US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
NO177005C (no) * | 1988-01-20 | 1995-07-05 | Bayer Ag | Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen |
-
1989
- 1989-01-05 NO NO89890046A patent/NO890046L/no unknown
- 1989-01-09 EP EP89100249A patent/EP0325129B1/de not_active Expired - Lifetime
- 1989-01-09 AT AT89100249T patent/ATE111081T1/de active
- 1989-01-09 DE DE58908290T patent/DE58908290D1/de not_active Expired - Fee Related
- 1989-01-09 ES ES89100249T patent/ES2058343T3/es not_active Expired - Lifetime
- 1989-01-17 IL IL8988971A patent/IL88971A/xx unknown
- 1989-01-17 US US07/298,453 patent/US4968689A/en not_active Expired - Fee Related
- 1989-01-17 NZ NZ227636A patent/NZ227636A/en unknown
- 1989-01-18 PT PT89478A patent/PT89478B/pt not_active IP Right Cessation
- 1989-01-18 FI FI890257A patent/FI92195C/sv not_active IP Right Cessation
- 1989-01-19 AU AU28613/89A patent/AU614810B2/en not_active Ceased
- 1989-01-19 JP JP1008769A patent/JP2712107B2/ja not_active Expired - Lifetime
- 1989-01-19 HU HU89213A patent/HU208691B/hu not_active IP Right Cessation
- 1989-01-19 KR KR1019890000549A patent/KR890011847A/ko not_active Application Discontinuation
- 1989-01-19 DK DK023289A patent/DK23289A/da not_active Application Discontinuation
- 1989-01-20 CN CN89100406A patent/CN1034716A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
NZ227636A (en) | 1990-09-26 |
HU208691B (en) | 1993-12-28 |
PT89478A (pt) | 1989-10-04 |
PT89478B (pt) | 1993-12-31 |
NO890046L (no) | 1989-07-21 |
EP0325129A2 (de) | 1989-07-26 |
ES2058343T3 (es) | 1994-11-01 |
CN1034716A (zh) | 1989-08-16 |
HUT50775A (en) | 1990-03-28 |
KR890011847A (ko) | 1989-08-22 |
FI92195C (sv) | 1994-10-10 |
FI890257A (sv) | 1989-07-21 |
EP0325129B1 (de) | 1994-09-07 |
US4968689A (en) | 1990-11-06 |
AU2861389A (en) | 1989-07-20 |
NO890046D0 (no) | 1989-01-05 |
ATE111081T1 (de) | 1994-09-15 |
AU614810B2 (en) | 1991-09-12 |
DE58908290D1 (de) | 1994-10-13 |
IL88971A (en) | 1993-07-08 |
EP0325129A3 (en) | 1990-12-19 |
DK23289A (da) | 1989-07-21 |
DK23289D0 (da) | 1989-01-19 |
FI890257A0 (sv) | 1989-01-18 |
IL88971A0 (en) | 1989-08-15 |
JPH021478A (ja) | 1990-01-05 |
JP2712107B2 (ja) | 1998-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI92196B (sv) | Förfarande för framställning av terapeutiskt användbara 2-pyridoner | |
FI93007B (sv) | Förfarande för framställning av terapeutiskt användbara substituerade pyridiner samt i förfarandet användbara mellanprodukter | |
FI92195B (sv) | Förfarande för framställning av terapeutiskt användbara pyridinderivat | |
US5120782A (en) | Substituted pyrrolo-pyridines pharmaceuticals | |
US4992462A (en) | Substituted pyrroles | |
US5260451A (en) | Substituted pyrrole compounds and use thereof in pharmaceutical compositions | |
US4968681A (en) | Substituted hydroxylamines | |
US4829081A (en) | Analogs of mevalonolactone and derivatives thereof | |
US5034399A (en) | Substituted 1,8-naphthyridines and their use in medicaments | |
JPH047348B2 (sv) | ||
KR890002640B1 (ko) | 치환된 이미다조[1, 5-a]피리딘의 제조방법 | |
US4988711A (en) | HMG-CoA reductare-inhibiting N-substituted N-amino-pyrroles | |
US5137881A (en) | Substituted pyrido-oxazine inhibitors of hmg-coa reductase | |
US5138090A (en) | Substituted biphenyls | |
US5164506A (en) | Substituted 2-pyridones and pyrid-2-thiones compounds | |
US5064841A (en) | HMG-COA reductase-inhibiting imino-substituted pyridines | |
US4973598A (en) | Substituted imidazolinones and imidazolinethiones | |
US5145857A (en) | Hmg-coa reductase-inhibiting substituted amino-pyridines | |
US4937255A (en) | Disubstituted pyrroles | |
US5502057A (en) | Polysubstituted pyridines useful for treating lipoproteinanaemia and arteriosclerosis | |
US5173495A (en) | 7-[(2,6-dialkyl-4-furyl or thienyl-pyridyl)]-3,5-di-(dihydroxy-6-enoates) useful for treating circulatory diseases | |
US5183897A (en) | Certain intermediate imino-substituted pyridines | |
AU630390B2 (en) | Substituted 2-pyridones and pyrid-2-thiones, processes for their preparation and their use in medicaments | |
DD283379A5 (de) | Verfahren zur herstellung disubstuierter pyridine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
BB | Publication of examined application | ||
MM | Patent lapsed | ||
MM | Patent lapsed |
Owner name: BAYER AKTIENGESELLSCHAFT |